The Measure of Plasma Concentrations Is Crucial in Managing Dabigatran Treatment in Non-Valvular Atrial Fibrillation

被引：0
|
作者：
Iosub, Diana [1 ]
Trotti, Rosa [2 ]
Piovella, Franco [2 ]
机构：
[1] Fdn IRCCS Policlin San Matteo, Pavia, Italy
[2] Fdn IRCCS Ist Neurol Nazl Casimiro Mondino, Pavia, Italy
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Cardioversion in Non-Valvular Atrial Fibrillation
    Klein, Hermann H.
    Trappe, Hans-Joachim
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2015, 112 (50): : 856 - +
  • [22] Population pharmacokinetic analysis for dabigatran etexilate in Chinese patients with non-valvular atrial fibrillation
    Liu, Ya-ou
    Xie, Qiu-fen
    Liu, Zhi-yan
    Wang, Zhe
    Mu, Guang-yan
    Zhang, Ya-tong
    Zhao, Zi-nan
    Yuan, Dong-dong
    Guo, Li-ping
    Wang, Na
    Xiang, Jing
    Song, Hong-tao
    Jiang, Jie
    Xiang, Qian
    Cui, Yi-min
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [23] Safety of dabigatran etexilate in frail older old patients with non-valvular atrial fibrillation
    Rodriguez Pascual, C.
    Paredes-Galan, E.
    Vilches-Moraga, A.
    Basalo-Carbajales, M. C.
    Guitian, A.
    EUROPEAN HEART JOURNAL, 2013, 34 : 96 - 96
  • [24] Use of dabigatran in patients with non-valvular atrial fibrillation: answers to frequently asked questions
    Deveci, Onur Sinan
    Demir, Mesut
    Aksoy, Mehmet
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2013, 41 : 25 - 33
  • [25] Comparative Effectiveness of Dabigatran and Rivaroxaban versus Warfarin in Patients With Non-Valvular Atrial Fibrillation
    Bengtson, Lindsay
    Chen, Lin
    MacLehose, Richard
    Lutsey, Pamela
    Alonso, Alvaro
    CIRCULATION, 2014, 130
  • [26] Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation
    Andersson, Niklas W.
    Svanstrom, Henrik
    Lund, Marie
    Pasternak, Bjorn
    Melbye, Mads
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 268 : 113 - 119
  • [27] Clinical and economic consequences of using dabigatran or rivaroxaban in patients with non-valvular atrial fibrillation
    Miguel, Luis Silva
    Ferreira, Jorge
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2016, 35 (03) : 141 - 148
  • [28] Cost-effectiveness of Dabigatran for Stroke Prevention in Non-valvular Atrial Fibrillation in Spain
    Gonzalez-Juanatey, Jose R.
    Alvarez-Sabin, Jose
    Lobos, Jose M.
    Martinez-Rubio, Antoni
    Reverter, Joan C.
    Oyagueez, Itziar
    Gonzalez-Rojas, Nuria
    Becerra, Virginia
    REVISTA ESPANOLA DE CARDIOLOGIA, 2012, 65 (10): : 901 - 910
  • [29] Factors affecting serum concentration of dabigatran in Asian patients with non-valvular atrial fibrillation
    Lin, Shin-Yi
    Tang, Sung-Chun
    Kuo, Ching-Hua
    Tsai, Li-Kai
    Yeh, Shin-Joe
    Shen, Li-Jivan
    Jeng, Jiann-Shing
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2019, 118 (07) : 1154 - 1160
  • [30] STROKE PROPHYLAXIS WITH WARFARIN AND DABIGATRAN FOR PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION - A COST ANALYSIS
    Ali, A. N.
    Bailey, C.
    Abdulhafiz, A. H.
    AGE AND AGEING, 2013, 42 : 31 - 31
12345